Press Releases

July 29, 2020 in Press Release

New Published Data Show NeuroPace’s RNS® System Provides Patients with Unprecedented Seizure Reduction and Improved Quality of Life

Personalized, data-driven treatment for refractory focal epilepsy demonstrates unprecedented real-world results and exceptional long-term clinical data MOUNTAIN VIEW, Calif. – July 27, 2020 – NeuroPace, Inc. today announced the publication of two seminal studies of the RNS System in prominent scientific journals Epilepsia and Neurology. The RNS System has been shown…
Read More
March 6, 2020 in Press Release

NeuroPace RNS System Receives FDA Approval for MRI Labeling, Allowing Thousands More Patients to Benefit from Personalized, Data-Driven Epilepsy Treatment

Full-body MRI opens up valuable medical imaging possibilities for RNS System patients MOUNTAIN VIEW, Calif. – March. 9, 2020 – NeuroPace, Inc., a Silicon Valley-based medical technology company, today announced that its RNS® System has received U.S. Food and Drug Administration (FDA) approval of MRI labeling for the RNS System,…
Read More
December 9, 2019 in Press Release

New Data Presented at the American Epilepsy Society Annual Meeting Demonstrate Unprecedented Efficacy Outcomes with the NeuroPace RNS System

Real-world experience with the RNS System reveals best outcomes to date of any neuromodulation device for focal seizures MOUNTAIN VIEW, Calif. — December 9, 2019 – NeuroPace, Inc. today announced that new data from a multicenter, real-world clinical study of the RNS System has demonstrated outcomes not previously seen with…
Read More
July 31, 2019 in Press Release

NeuroPace Appoints Mark Saxton as Vice President of Sales

Industry veteran to drive business development, strategy and enhance customer experience MOUNTAIN VIEW, Calif. — July 30, 2019 – NeuroPace, Inc., a Silicon Valley-based medical technology company, today announced the appointment of Mark Saxton as the company’s Vice President of Sales. Mr. Saxton is an accomplished medical device industry executive…
Read More
July 24, 2019 in Press Release

NeuroPace Announces Michael Favet as CEO

Frank Fischer appointed Chairman of Board of Directors MOUNTAIN VIEW, Calif. - July 24, 2019 (BUSINESS WIRE)--NeuroPace, Inc., a Silicon Valley-based medical technology company, today announced the appointment of Michael Favet as Chief Executive Officer. Frank Fischer, after 20 years serving as CEO, continues with NeuroPace as Chairman of the…
Read More
July 10, 2019 in Press Release

NIH Study to Utilize NeuroPace RNS® System for Research on the Brain’s Reward System

Study Aims to Assess Whether Closed-Loop Neuromodulation Could Help Manage
 Medically Refractory Obesity MOUNTAIN VIEW, Calif. — July 10, 2019 – NeuroPace, Inc., a Silicon Valley-based medical technology company, today announced that the company’s RNS® System, a closed-loop neuromodulation technology approved to treat adults with medically refractory focal onset epilepsy,…
Read More
May 9, 2019 in Press Release

NeuroPace Shares Positive Data from Studies of the RNS System at the American Academy of Neurology 2019 Annual Meeting

Results Demonstrate Significant Seizure Reduction in Adults with Drug-Resistant Epilepsy; Insights into the Human Brain MOUNTAIN VIEW, Calif. — May 9, 2019 – NeuroPace, Inc., a Silicon Valley-based medical technology company, presented long-term clinical results demonstrating that the RNS® System for refractory epilepsy significantly reduces seizure frequency in patients, with…
Read More
February 12, 2019 in Press Release

NeuroPace Announces New Category I CPT Code from AMA for Electrocorticography from an Implanted Brain Neurostimulator

Supports Value of Insights Provided by Brain Recordings from the NeuroPace RNS® System for Drug-Resistant Epilepsy MOUNTAIN VIEW, Calif. – February 12, 2019 – NeuroPace, Inc., a Silicon Valley-based medical technology company, today announced that the American Medical Association (AMA) has issued a new Category I Current Procedural Terminology (CPT®) code for electrocorticography…
Read More
December 2, 2018 in Press Release

NeuroPace Announces Final Results from the Largest Prospective Clinical Study in the Field of Neuromodulation with 9-Year Follow-Up at the 2018 American Epilepsy Society Annual Meeting

More than One-Third of Drug-Resistant Epilepsy Patients Achieved ≥90% Seizure Reduction with the RNS System. NEW ORLEANS--(BUSINESS WIRE)--American Epilepsy Society Annual Meeting, Booth 519 — NeuroPace, Inc., a Silicon Valley-based medical technology company that recently launched the Next-Gen RNS® System for refractory epilepsy, today announced complete results from its groundbreaking…
Read More
June 1, 2018 in Press Release

NeuroPace Launches Next Generation RNS System, the World’s Only Brain-Computer Interface for the Treatment of Refractory Epilepsy

Next Gen RNS System provides unprecedented brain data with long-lasting, 8-year battery life. MOUNTAIN VIEW, Calif -- June 1, 2018 – NeuroPace, Inc., a Silicon Valley-based medical technology company, today announced the launch of its Next Gen RNS® System for the treatment of refractory epilepsy, which affects an estimated 1…
Read More
December 5, 2017 in Press Release

NeuroPace Unveils 8-Year Prospective Clinical Outcomes and Groundbreaking Research Using Deep Learning Algorithms to Identify Seizure Biomarkers

WASHINGTON--(EON: Enhanced Online News)--American Epilepsy Society Annual Meeting, Booth 1101--NeuroPace, Inc., a Silicon Valley-based medical technology company that developed the world’s first and only closed-loop brain-responsive neurostimulation system for epilepsy, today announces 5 poster presentations, including new 8-year prospective clinical trial data presented at the American Epilepsy Society’s (AES) Annual…
Read More
October 23, 2017 in Press Release, Uncategorized

NeuroPace Closes $74 Million Equity Funding to Accelerate Patient Access to the World’s First Brain-Responsive Neurostimulation System to Treat Epilepsy

MOUNTAIN VIEW, Calif. – October 24, 2017 – NeuroPace, Inc., a Silicon Valley-based medical technology company that developed the world’s first and only closed-loop brain-responsive neurostimulation system shown to significantly reduce seizure frequency, announced today that it closed a $74 million round of funding led by the KCK Group and…
Read More
February 27, 2017 in Press Release

NeuroPace Announces 1,000th Patient Treated with RNS System for Medically Refractory Epilepsy

MOUNTAIN VIEW, California – February 20, 2017 – NeuroPace, Inc. announced today that the 1000th patient has been treated with its award-winning RNS® System, approved by the FDA in November 2013. Similar to a pacemaker that monitors and responds to heart rhythms, the RNS System is the first and only…
Read More
December 7, 2016 in Press Release

NeuroPace, Inc. Announces Results of 7 Years of Clinical Trial Follow-up Demonstrating 72 Percent Seizure Reduction with the RNS® System – December 4, 2016

Read More